Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) is pleased to announce that the eight incumbent directors of the Company were elected at the Company’s annual general meeting (the “Meeting”) held on June 7, 2021.
Detailed results of the vote by proxy for the election of directors are provided below:
Nominee |
Votes For (%) |
Votes Withheld (%) |
||||||
George M. Milne |
80.91 |
|
|
|
19.09 |
|||
Peter Greenleaf |
92.18 |
|
|
|
7.82 |
|||
David R.W. Jayne |
93.00 |
|
|
|
7.00 |
|||
Joseph P. Hagan |
87.15 |
|
|
|
12.85 |
|||
Daniel G. Billen |
95.64 |
|
|
|
4.36 |
|||
R. Hector MacKay-Dunn |
93.27 |
|
|
|
6.73 |
|||
Jill Leversage |
95.05 |
|
|
|
4.95 |
|||
Timothy P. Walbert |
89.56 |
|
|
|
10.44 |
In addition, following final tallies of votes, all other matters voted on at the Meeting were also approved. Voting results on all matters voted on at the Meeting will be filed on SEDAR at www.sedar.com and EDGAR at www.edgar.com.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210607005782/en/
Contacts
Investors:
Glenn Schulman, PharmD, MPH
Investor Relations & Corporate Communications, Aurinia
gschulman@auriniapharma.com
Media:
Dana Lynch
Corporate Communications, Aurinia
dlynch@auriniapharma.com
